Systemic Lupus Erythematosus

Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus

Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus

By

Outcomes in systemic lupus erythematosus are largely influenced by level of poverty, type of neighborhood of residence, and chronic stress.

SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity

SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity

By

To assess validity of SLE-DAS, investigators performed a Spearman's correlation between SLE-DAS, PGA, and SLEDAI-2K at the last follow-up visit.

Cardiac Screening May Not Be Beneficial in SLE With Anti-Ro Antibodies

Cardiac Screening May Not Be Beneficial in SLE With Anti-Ro Antibodies

By

Cardiac screening in patients with systemic lupus erythematosus and anti-Ro-positive antibodies does not appear to be beneficial in clinical practice.

Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study

Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study

By

Baricitinib 4 mg was safe and effective in patients with systemic lupus erythematosus.

Determining Elevated Thrombotic Risk in Systemic Lupus Erythematosus

Determining Elevated Thrombotic Risk in Systemic Lupus Erythematosus

By

Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.

Obesity May Not Be Associated With Development of Lupus Nephritis

Obesity May Not Be Associated With Development of Lupus Nephritis

By

Obesity is not associated with the development of lupus nephritis among patients with systemic lupus erythematosus.

Examining Trends of Histologic Presentation, Renal Outcomes in Lupus Nephritis

Examining Trends of Histologic Presentation, Renal Outcomes in Lupus Nephritis

By

Investigators sought to evaluate changes in demographic, clinical, and histologic presentation in patients with lupus nephritis between 1970 and 2016.

Anti-dsDNA Antibodies Correlated With Clinical, Laboratory Parameters in SLE

Anti-dsDNA Antibodies Correlated With Clinical, Laboratory Parameters in SLE

By

Female patients with systemic lupus erythematosus who had musculoskeletal symptoms or positive antiphospholipid antibodies demonstrated higher titers of anti-double-stranded DNA antibodies.

Managing Cognitive Dysfunction in Systemic Lupus Erythematosus

Managing Cognitive Dysfunction in Systemic Lupus Erythematosus

By

The pathogenic pathways of SLE-related cognitive dysfunction are yet to be fully elucidated, but vasculopathy, antibody-mediated neurotoxicity, impairments in cytokine signaling, and complement abnormalities have been proposed as contributing factors.

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

By

Recent evidence suggests that systemic sclerosis and SLE in pulmonary arterial hypertension should be considered separate diseases.

Clinician Roundtable: Improving Quality of Life in Systemic Lupus Erythematosus

Clinician Roundtable: Improving Quality of Life in Systemic Lupus Erythematosus

By

Quality of life measurements capture unique information about systemic lupus erythematosus that are not included in disease activity or damage evaluations.

Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression

Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression

By

The relationship between pain and cognitive dysfunction was explained by sleep disturbance and depressive symptoms.

Bisphosphonate, Vitamin D Combination Therapy May Prevent Atherosclerosis in SLE

Bisphosphonate, Vitamin D Combination Therapy May Prevent Atherosclerosis in SLE

By

Bisphosphonates and vitamin D may help prevent atherosclerosis in patients with systemic lupus erythematosus.

ACR Provisional Criteria: Global Flares in Childhood-Onset SLE

ACR Provisional Criteria: Global Flares in Childhood-Onset SLE

By

Provisional criteria for global flares in patients with childhood-onset systemic lupus erythematosus are now available from the ACR.

Effects of SLE Diagnosis Examined in Antiphospholipid Antibody-Positive Patients

Effects of SLE Diagnosis Examined in Antiphospholipid Antibody-Positive Patients

By

Researchers compared the clinical, laboratory, and treatment characteristics of antiphospholipid antibody-positive patients with or without SLE.

Repeat Antibody Testing May Be Unnecessary for Some Patients With SLE

Repeat Antibody Testing May Be Unnecessary for Some Patients With SLE

By

Data show that anti-ENA results change infrequently, especially following 1 or more negative tests.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Belimumab Effective for Hypocomplementemic, Anti-dsDNA-Positive SLE

Belimumab Effective for Hypocomplementemic, Anti-dsDNA-Positive SLE

By

Weekly belimumab treatment was safe and effective and superior to placebo for reducing disease activity over 52 weeks in patients who were hypocomplementemic and anti-dsDNA positive.

Comparing Statin Prescriptions, Lipid Testing in SLE vs Diabetes

Comparing Statin Prescriptions, Lipid Testing in SLE vs Diabetes

By

Researchers investigated whether patients with SLE receive lipid testing and statin prescriptions comparably with patients with diabetes.

Incident Proteinuria in SLE May Be Predicted by Certain Clinical, Serological Manifestations

Incident Proteinuria in SLE May Be Predicted by Certain Clinical, Serological Manifestations

By

Certain clinical and serological markers were predictive of future incident proteinuria in patients with systemic lupus erythematosus.

Lupus Is a Leading Cause of Death in Young Women

Lupus Is a Leading Cause of Death in Young Women

Systemic lupus erythematosus is among the top 20 leading causes of death in women between the ages of 5 and 64 years in the United States.

Identifying Social Determinants of Mortality in Systemic Lupus Erythematosus

Identifying Social Determinants of Mortality in Systemic Lupus Erythematosus

By

Investigators suggest several mechanisms for the contribution of poverty to high mortality rates in patients with systemic lupus erythematosus.

Quality of SLE Care Assessed in Specialized Lupus vs General Rheumatology Clinic

Quality of SLE Care Assessed in Specialized Lupus vs General Rheumatology Clinic

By

Researchers compared the quality of care received by patients with systemic lupus erythematosus in 2 settings within the same academic institution.

Precision Medicine in Rheumatology: Personalizing Treatment for Improved Clinical Outcomes

Precision Medicine in Rheumatology: Personalizing Treatment for Improved Clinical Outcomes

By

Judith A. James, MD, PhD, discusses the developments of precision medicine in rheumatology at the 2018 State-of-the-Art Clinical Symposium.

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.

Metabolic Syndrome Frequency Assessed in Systemic Lupus Erythematosus

Metabolic Syndrome Frequency Assessed in Systemic Lupus Erythematosus

By

The frequency of metabolic syndrome among patients with SLE was approximately 45%.

Efficacy of Blisibimod Therapy Evaluated in Systemic Lupus Erythematosus

Efficacy of Blisibimod Therapy Evaluated in Systemic Lupus Erythematosus

By

Blisibimod was effective in patients with SLE in terms of steroid reduction, decreased proteinuria, and improvement in serological markers.

Ubiquitination in NETs May Affect Adaptive Immune Responses in SLE

Ubiquitination in NETs May Affect Adaptive Immune Responses in SLE

By

Neutrophil extracellular traps contain ubiquitinated proteins with a lower expression of polyubiquitinated proteins in patients with SLE.

Women With SLE Become Pregnant More Easily vs Women With Rheumatoid Arthritis

Women With SLE Become Pregnant More Easily vs Women With Rheumatoid Arthritis

By

Researchers examined differences in the ability to get pregnant in women with systemic lupus erythematosus and rheumatoid arthritis.

Ofatumumab Safe, Effective for B Cell Depletion in Rituximab-Intolerant SLE

Ofatumumab Safe, Effective for B Cell Depletion in Rituximab-Intolerant SLE

By

Ofatumumab was a well-tolerated, safe, and effective alternative to rituximab for B cell depletion therapy.

Sign Up for Free e-newsletters